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Introduction
Interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6R)
have been demonstrated to play a significant role as
inflammatory mediators in systemic juvenile idiopathic
arthritis (SJIA). Tocilizumab, a humanized anti-IL-6
receptor antibody, becomes a new biologic treatment for
SJIA nowadays but the correlation of serum IL-6 levels
and serum sIL-6R levels with disease activity in SJIA
with and without tocilizumab treatment are still unclear.
Objectives
To determine the correlations of serum IL-6 levels and
serum sIL-6R levels with disease activity in SJIA patients
with and without tocilizumab treatment
Methods
SJIA patients in pediatric rheumatology clinic,
Ramathibodi hospital between September 2011 and
June 2013 were enrolled in this study. Patients were
followed up three times in 2-3 months interval. Fifteen
healthy children were included as normal controls.
Demographic data was collected. During the visit,
patients were evaluated according to Juvenile Arthritis
Disease Activity Score-71 (JADAS-71) and blood sam-
plings were collected for complete blood count, ery-
throcyte sedimentation rate, IL-6 levels, and sIL-6R
levels, then patients were categorized into 4 groups; 1)
active disease with systemic features and arthritis 2)
active disease with only arthritis 3) remission on medi-
cation 4) remission off medication
Results
Forty-two SJIA patients, 131 blood samplings were
included in this study. Seventeen patients (40%) were
treated with tocilizumab during the study. Serum IL-6
levels in patients without tocilizumab treatment signifi-
cantly elevated in active disease with systemic features
and arthritis [median (IQR) = 101.8 (303.2) pg/mL]
when compared to active disease with only arthritis
[median (IQR) = 4.5 (23) pg/mL], and remission on
medication [median (IQR) = 1.5 (0.55) pg/mL], whereas
serum IL-6 levels in patients with tocilizumab treatment
were not different between groups but there were signif-
icantly different when compared to healthy children
(p < 0.05). In addition, the correlation between serum IL-6
levels and JADAS-71 in patients without tocilizumab treat-
ment (r = 0.71, p < 0.001) was stronger than patients with
tocilizumab treatment (r = 0.42, p = 0.01). Serum sIL-6R
levels in SJIA patients with and without tocilizumab treat-
ment were significantly higher when compared to healthy
children (p < 0.05). Interestingly, in patients with tocilizu-
mab treatment, serum sIL-6R levels were extremely higher
[median (IQR) = 1,110.3 (840.2) ng/mL] than patients
without tocilizumab treatment [median (IQR) = 94.2
(82.7) ng/mL].
Conclusion
The correlation between serum IL-6 levels and disease
activity in patients without tocilizumab treatment was
stronger than patients with tocilizumab treatment. In
addition, serum sIL-6R levels in patients with tocilizumab
treatment were extremely higher than patients without
tocilizumab treatment.
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